AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8847044
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy with G-CSF
Trial: 6896965
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of morphine 2 mg
Trial: 6896965
Drug: Intrathecal application
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal application of morphine
Trial: 31829095
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow mesenchymal stem cells (MSCINJ) with intensive atorvastatin (80 mg/d)
Trial: 30175557
Drug: High CHO
RxNorm normalized name: High choriolytic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CHO (HCHO: 415 g) during recovery and moderate-intensity exercise (120SS)
Trial: 20662675
Drug: Local infiltrations
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltrations of 1 mL articaine HCl 4% with epinephrine 1/200,000 to the ipsilateral mylohyoid and buccal nerves
Trial: 20662675
Drug: Inferior alveolar
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inferior alveolar and buccal nerve blocks
Trial: 19427768
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (mean HbA1c reduction of 0.9%)
Trial: 2678309
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + hydrochlorothiazide 15 mg/die
Trial: 2678309
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg/die
Trial: 18163165
Drug: MTX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX plus FA (20 mg/week)
Trial: 1195163
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment options
Trial: 25605698
Drug: DEX-IV (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX-IV (intravenous injection of dexamethasone 0.5 mg/kg, maximum dose 24 mg)
Trial: 17077809
Drug: Olanzapine 2.5
RxNorm normalized name: olanzapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg/day
Trial: 9169300
Drug: Olanzapine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (all doses)
Trial: 11719736
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 8 days
Trial: 11719736
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg 4 times daily on day 8
Trial: 27346078
Drug: Corn starch
RxNorm normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn starch fiber at 90 g/day (multiple-serving study)
Trial: 27346078
Drug: Corn starch
RxNorm normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn starch fiber at 50 g/day (single-dose study)
Trial: 27346078
Drug: Corn starch
RxNorm normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn starch fiber at 60 g (multiple servings)
Trial: 22871048
Drug: Polyherbal Unani
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyherbal Unani formulation (topical application)
Trial: 22871048
Drug: Sodium thiosulphate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium thiosulphate lotion (20%) (control group)
Trial: 17091134
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction (CA) toothbrush
Trial: 11567957
Drug: Latanoprost 50
RxNorm normalized name: Latanoprost 50 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 50 microg/ml applied four times daily
Trial: 11567957
Drug: Latanoprost 50
RxNorm normalized name: Latanoprost 50 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 50 microg/ml applied once daily
Trial: 11567957
Drug: Latanoprost 50
RxNorm normalized name: Latanoprost 50 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 50 microg/ml applied once daily after 3 weeks without treatment
Trial: 8501156
Drug: Loxiglumide (CCK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK receptor antagonist)
Trial: 21978235
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.5% drops for 3 months (group 1)
Trial: 15632770
Drug: CR2 (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR2 (weekly supervised sessions for 26 weeks followed by one supervised session per month for the remaining 26 weeks)
Trial: 11719356
Drug: Intravenous Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Cyclosporine A (CsA)
Trial: 27601379
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effect
Trial: 28976412
Drug: Epitiram (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epitiram (generic drug)
Trial: 21815864
Drug: Telaprevir (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (3 × 750 mg/day) alone
Trial: 11217910
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (SALM/FP) via Diskus inhaler 50/100 microg, twice daily
Trial: 11217910
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 microg via chlorofluorocarbon MDI, twice daily
Trial: 8019763
Drug: Intravenous lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lithium (4 mEq kg‐1) in diabetic rats
Trial: 8019763
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (0.5 g kg‐1) in both groups
Trial: 8019763
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment in both normal and diabetic rats
Trial: 30804032
Drug: Surgeons receiving
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeons receiving a report detailing patients' goals and treatment preferences
Trial: 30804032
Drug: Surgeons not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeons not receiving a report detailing patients' goals and treatment preferences
Trial: 23745526
Drug: Arformoterol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arformoterol aerosol solution (15μg/2mL) via nebulizer
Trial: 11393591
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day)
Trial: 12430728
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied once daily for 3 weeks
Trial: 12430728
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied twice daily for 3 weeks
Trial: 9820354
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg oral ciprofloxacin
Trial: 31483964
Drug: Mitapivat 50
RxNorm normalized name: mitapivat 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitapivat 50 mg twice daily
Trial: 31483964
Drug: Mitapivat 300
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitapivat 300 mg twice daily
Trial: 12048127
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg/day
Trial: 7926408
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ivermectine (200 mcg/Kg)
Trial: 3096764
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (1.5 mg/Kg/day) for 18 days
Trial: 27721228
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg/d
Trial: 12144586
Drug: Prucalopride 1
RxNorm normalized name: prucalopride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 1 mg daily for 4 weeks
Trial: 28445354
Drug: Tumescent saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent saline solution with epinephrine (1:1 million) and lidocaine (0.05%) (group 2)
Trial: 28445354
Drug: Tumescent saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescent saline solution with epinephrine (1:1 million) (group 1)
Trial: 26626301
Drug: Probiotics intervention
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics intervention (tablet A and tablet B)
Trial: 24005139
Drug: Non steroid
RxNorm normalized name: Proctofoam 1% Non Steroid Hemorrhoidal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non steroid cream
Trial: 24005139
Drug: Hydrocortisone Butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone Butyrate 0.1% Cream
Trial: 17154745
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy plus manuals (NRT + MAN)
Trial: 12649521
Drug: Approximately 2
RxNorm normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 hours of therapy per week for 22.9 weeks
Trial: 12649521
Drug: Total of
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 98.4 hours of therapy
Trial: 12649521
Drug: Total of
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 43.6 hours of therapy
Trial: 12649521
Drug: Total length
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total length of therapy time
Trial: 12649521
Drug: Hours of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hours of therapy provided in a week
Trial: 12649521
Drug: Total number
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total number of hours of therapy
Trial: 1576048
Drug: ICI 170,809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 170,809 (7 mg)
Trial: 2416331
Drug: Tofisopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofisopam (100 mg)
Trial: 31878961
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving an educational intervention and continuing usual treatment
Trial: 29431785
Drug: Glucono‐δ‐lactone (GDL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucono‐δ‐lactone (GDL) 2000 mg day‐1
Trial: 20157833
Drug: Saline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.2 ml kg(‐1)
Trial: 10599933
Drug: Valerian root
RxNorm normalized name: Valerian Root
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian root extract (VRE) 600 mg LI 156
Trial: 10599933
Drug: Flunitrazepam (FNZ)
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (FNZ) 1 mg
Trial: 7015844
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus antacid (Maalox)
Trial: 25173770
Drug: Valerian root
RxNorm normalized name: Valerian Root
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian root extract (530 mg per capsule, 1,060 mg daily)
Trial: 23736751
Drug: TIMT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMT + treatment as usual (TAU)
Trial: 15481447
Drug: PBSC collection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBSC collection after intermediate-dose cytarabine and mitoxantrone (group B)
Trial: 15481447
Drug: PBSC collection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBSC collection after induction and/or consolidation chemotherapy (group A)
Trial: 8787684
Drug: Oltipraz 125
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 125 mg/m2
Trial: 8787684
Drug: Oltipraz 250
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 250 mg/m2
Trial: 2731461
Drug: Mixed meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meal containing 80 g complex carbohydrates
Trial: 2731461
Drug: Mixed meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meal containing 140 g complex carbohydrates
Trial: 30987685
Drug: m-health medication
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-health medication adherence intervention
Trial: 25422825
Drug: 6-mm long
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm long implants
Trial: 25422826
Drug: 10-mm long
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mm long implants
Trial: 23194203
Drug: Propofol (25.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (25.5 µg/kg/minute)
Trial: 11501687
Drug: Haloperidol (1.4±0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1.4±0.7 mg/day)
Trial: 8244516
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg PO TID for 7 days)
Trial: 2700702
Drug: Bromelaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelaine (3 x 80 mg daily for 6 days)
Trial: 25881690
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Mitiglinide + Sitagliptin)
Trial: 23883803
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid (Ns) + antihistamine (Ah)
Trial: 23883803
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid (Ns)
Trial: 28426856
Drug: Oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral voriconazole
Trial: 22042283
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intravenous amphotericin B (AmB)
Trial: 15660766
Drug: Zonisamide 500
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 500 mg/day
Trial: 16316744
Drug: Zonisamide 400-600
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 400-600 mg/day
Trial: 15013305
Drug: IV thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thymoglobulin (ATG 5 mg/kg/d) plus methylprednisolone (500 mg/d) plus azathiopurine (2 mg/kg/d) on days 0 and 1 after renal transplantation.
Trial: 11312402
Drug: Atopic asthmatics
RxNorm normalized name: Atopica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic asthmatics treated with beta(2) agonists alone
Trial: 9562357
Drug: Salbutamol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.4 mg x 3) administered 10 min before exercise
Trial: 29035633
Drug: Technology assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology assisted therapy for separation anxiety (TTSA)
Trial: 22539545
Drug: Cilostazol treatment
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol treatment
Trial: 28073668
Drug: Cilostazol-free treatment
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol-free treatment
Trial: 23506518
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and postoperative physical therapy
Trial: 19496829
Drug: Other active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other active agents
Trial: 9291281
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy with standardized cat dander extract
Trial: 3105558
Drug: Astemizole 5
RxNorm normalized name: astemizole 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 5 mg/d
Trial: 3105558
Drug: Astemizole 20
RxNorm normalized name: astemizole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 20 mg/d
Trial: 29587288
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium thiosulfate (IV STS) 12.5 g during the last HD hour twice weekly for 6 months
Trial: 29587288
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium thiosulfate (IV STS)
Trial: 25373724
Drug: Anodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal transcranial direct current stimulation (tDCS) combined with standard treatment
Trial: 25373724
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with standard treatment
Trial: 22575567
Drug: S(+)-ketamine pharmacodynamics
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)-ketamine pharmacodynamics
Trial: 17390761
Drug: Fexofenadine HCl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl, 180 mg
Trial: 27349705
Drug: Pitavastatin monotherapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin monotherapy (target LDL-C 90-100mg/dL)
Trial: 21996058
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (EX) - attended exercise facility three times/week for 52 weeks, daily jumping exercises at home, calcium supplementation.
Trial: 11966923
Drug: Powered toothbrush
RxNorm normalized name: Pro Clean Spinbrush Powered Toothbrush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powered toothbrush (Braun Oral‐B Plaque Remover 3‐D)
Trial: 11966923
Drug: Manual soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual soft toothbrush (Oral‐B Squish‐grip brush)
Trial: 1639941
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg cetrorelix
Trial: 1639941
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg cetrorelix
Trial: 1639941
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg cetrorelix
Trial: 1639941
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg cetrorelix
Trial: 1639941
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg cetrorelix
Trial: 6089307
Drug: Enalapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (40 mg daily)
Trial: 6089307
Drug: Lisinopril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (40 mg daily)
Trial: 6089307
Drug: Both enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both enalapril and lisinopril
Trial: 19483453
Drug: Intraperitoneal injection
RxNorm normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of 0.25% bupivacaine (40 ml) and 20 ml in 4 ports (5 ml each)
Trial: 19483453
Drug: Intraperitoneal injection
RxNorm normalized name: CALCIUM GLUCONATE 23 g in 100 mL INTRAPERITONEAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection of 0.25% bupivacaine
Trial: 11504277
Drug: Buspirone extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone extended-release (ER) formulation
Trial: 9489934
Drug: Nicotine cigarette
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine cigarette (0.8 mg nicotine)
Trial: 2336928
Drug: 0.25% L-timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% L-timolol
Trial: 7212475
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg dose of verapamil
Trial: 28768334
Drug: Individual face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual face-to-face cognitive behavioral therapy (CBT)